Helicos Reports $1.1M in Q3 Revenue; Rules Out Company Sale for Now as Prospects Improve

The company also indicated that it is weighing price reductions for its instrument and plans to introduce new reagent kits next year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.